$4.46
0.10%
Nasdaq, Mon, Nov 25 2024
ISIN
US68232V3069
Symbol
ONTX
Sector
Industry

Onconova Therapeutics Inc. Target price 2024 - Analyst rating & recommendation

Onconova Therapeutics Inc. Classifications & Recommendation:

Buy
100%

Onconova Therapeutics Inc. Price Target

Target Price $7.00
Price $4.46
Potential
Number of Estimates 1
1 Analyst has issued a Onconova Therapeutics Inc. price target 2025. The average Onconova Therapeutics Inc. target price is $7.00. This is higher than the current stock price.
A rating was issued by 1 analysts: 1 Analysts recommend Onconova Therapeutics Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Onconova Therapeutics Inc. stock has an average upside potential 2025 of . Most analysts recommend the Onconova Therapeutics Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.23 0.23
0.00% 0.00%
Net Margin -29,733.52% -192,339.13%
2,380.22% 546.88%

1 Analyst has issued a sales forecast Onconova Therapeutics Inc. 2024 . The average Onconova Therapeutics Inc. sales estimate is

$230k
Unlock
. This is
0.00% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$230k 0.00%
Unlock
, the lowest is
$230k 0.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $230k 0.00%
2024
$230k 0.00%
Unlock
2025
$230k 0.00%
Unlock

1 Analyst has issued a net profit forecast Onconova Therapeutics Inc. 2024 . The average Onconova Therapeutics Inc. net profit estimate is

$-442m
Unlock
. This is
3.29% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-442m 3.29%
Unlock
, the lowest is
$-442m 3.29%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-68.4m 2,380.22%
2024
$-442m 546.88%
Unlock
2025
$-102m 76.88%
Unlock

Net Margin

2023 -29,733.52% 2,380.22%
2024
-192,339.13% 546.88%
Unlock
2025
-44,461.96% 76.88%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -22.57 -146.00
2,380.22% 546.88%
P/E negative
EV/Sales 35.13

1 Analysts have issued a Onconova Therapeutics Inc. forecast for earnings per share. The average Onconova Therapeutics Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-146.00
Unlock
. This is
3.29% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-146.00 3.29%
Unlock
, the lowest is
$-146.00 3.29%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-22.57 2,380.22%
2024
$-146.00 546.88%
Unlock
2025
$-33.75 76.88%
Unlock

P/E ratio

Current -0.03 95.71%
2024
-0.03 0.00%
Unlock
2025
-0.13 333.33%
Unlock

Based on analysts' sales estimates for 2024, the Onconova Therapeutics Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

35.13
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
58.65
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 35.13 172.54%
2024
35.13 0.00%
Unlock
2025
35.13 0.00%
Unlock

P/S ratio

Current 58.65 4.33%
2024
58.65 0.00%
Unlock
2025
58.65 0.00%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today